Acute Ischaemic Stroke
15
0
0
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.7%
1 terminated out of 15 trials
90.9%
+4.4% vs benchmark
40%
6 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke
Ultra-early Chest CT for SAP Prediction
Combined tDCS+PNS After Acute Stroke
Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study
Effects of Heart Rate Variability Biofeedback in Patients With Acute Ischemic Stroke
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Imatinib in Acute Ischaemic Stroke
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion
Magnetic Resonance Post-contrast Vascular Hyperintensities at 3 T: a Sensitive Sign of Vascular Occlusion in Acute Ischaemic Stroke
Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset
Pragmatic Ischaemic Stroke Thrombectomy Evaluation